Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations

Nagsen Gautam, Pavan Puligujja, Shantanu Balkundi, Rhishikesh Thakare, Xin Ming Liu, Howard S Fox, JoEllyn M McMillan, Howard Eliot Gendelman, Yazen Alnouti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The drug delivery platform for folic acid (FA)-coated nanoformulated ritonavir (RTV)-boosted atazanavir (FA-nanoATV/r) using poloxamer 407 was developed to enhance cell and tissue targeting for a range of antiretroviral drugs. Such formulations would serve to extend the drug half-life while improving the pharmacokinetic profile and biodistribution to reservoirs of human immunodeficiency virus (HIV) infection. To this end, we now report enhanced pharmacokinetics and drug biodistribution with limited local and systemic toxicities of this novel nanoformulation. The use of FA as a targeting ligand for nanoATV/r resulted in plasma and tissue drug concentrations up to 200-fold higher compared to equimolar doses of native drug. In addition, ATV and RTV concentrations in plasma from mice on a folate-deficient diet were up to 23-fold higher for mice administered FA-nanoATV/r than for mice on a normal diet. Compared to earlier nanoATV/r formulations, FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations. In a drug interaction study, ATV plasma and tissue concentrations were up to 5-fold higher in mice treated with FA-nanoATV/r than in mice treated with FA-nanoATV alone. As observed in mice, enhanced and sustained plasma concentrations of ATV were observed in monkeys. NanoATV/r was associated with transient local inflammation at the site of injection. There were no systemic adverse reactions associated with up to 10 weeks of chronic exposure of mice or monkeys to FA-nanoATV/r. /AAC.04108-14.

Original languageEnglish (US)
Pages (from-to)7510-7519
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Folic Acid
Pharmacokinetics
Pharmaceutical Preparations
Ritonavir
Haplorhini
Diet
Poloxamer
Virus Diseases
Drug Interactions
Half-Life
HIV
Ligands
Inflammation
Injections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. / Gautam, Nagsen; Puligujja, Pavan; Balkundi, Shantanu; Thakare, Rhishikesh; Liu, Xin Ming; Fox, Howard S; McMillan, JoEllyn M; Gendelman, Howard Eliot; Alnouti, Yazen.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 12, 01.12.2014, p. 7510-7519.

Research output: Contribution to journalArticle

@article{c7827ad2860a4784bee889da64e9bbfc,
title = "Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations",
abstract = "The drug delivery platform for folic acid (FA)-coated nanoformulated ritonavir (RTV)-boosted atazanavir (FA-nanoATV/r) using poloxamer 407 was developed to enhance cell and tissue targeting for a range of antiretroviral drugs. Such formulations would serve to extend the drug half-life while improving the pharmacokinetic profile and biodistribution to reservoirs of human immunodeficiency virus (HIV) infection. To this end, we now report enhanced pharmacokinetics and drug biodistribution with limited local and systemic toxicities of this novel nanoformulation. The use of FA as a targeting ligand for nanoATV/r resulted in plasma and tissue drug concentrations up to 200-fold higher compared to equimolar doses of native drug. In addition, ATV and RTV concentrations in plasma from mice on a folate-deficient diet were up to 23-fold higher for mice administered FA-nanoATV/r than for mice on a normal diet. Compared to earlier nanoATV/r formulations, FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations. In a drug interaction study, ATV plasma and tissue concentrations were up to 5-fold higher in mice treated with FA-nanoATV/r than in mice treated with FA-nanoATV alone. As observed in mice, enhanced and sustained plasma concentrations of ATV were observed in monkeys. NanoATV/r was associated with transient local inflammation at the site of injection. There were no systemic adverse reactions associated with up to 10 weeks of chronic exposure of mice or monkeys to FA-nanoATV/r. /AAC.04108-14.",
author = "Nagsen Gautam and Pavan Puligujja and Shantanu Balkundi and Rhishikesh Thakare and Liu, {Xin Ming} and Fox, {Howard S} and McMillan, {JoEllyn M} and Gendelman, {Howard Eliot} and Yazen Alnouti",
year = "2014",
month = "12",
day = "1",
doi = "10.1128/AAC.04108-14",
language = "English (US)",
volume = "58",
pages = "7510--7519",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations

AU - Gautam, Nagsen

AU - Puligujja, Pavan

AU - Balkundi, Shantanu

AU - Thakare, Rhishikesh

AU - Liu, Xin Ming

AU - Fox, Howard S

AU - McMillan, JoEllyn M

AU - Gendelman, Howard Eliot

AU - Alnouti, Yazen

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The drug delivery platform for folic acid (FA)-coated nanoformulated ritonavir (RTV)-boosted atazanavir (FA-nanoATV/r) using poloxamer 407 was developed to enhance cell and tissue targeting for a range of antiretroviral drugs. Such formulations would serve to extend the drug half-life while improving the pharmacokinetic profile and biodistribution to reservoirs of human immunodeficiency virus (HIV) infection. To this end, we now report enhanced pharmacokinetics and drug biodistribution with limited local and systemic toxicities of this novel nanoformulation. The use of FA as a targeting ligand for nanoATV/r resulted in plasma and tissue drug concentrations up to 200-fold higher compared to equimolar doses of native drug. In addition, ATV and RTV concentrations in plasma from mice on a folate-deficient diet were up to 23-fold higher for mice administered FA-nanoATV/r than for mice on a normal diet. Compared to earlier nanoATV/r formulations, FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations. In a drug interaction study, ATV plasma and tissue concentrations were up to 5-fold higher in mice treated with FA-nanoATV/r than in mice treated with FA-nanoATV alone. As observed in mice, enhanced and sustained plasma concentrations of ATV were observed in monkeys. NanoATV/r was associated with transient local inflammation at the site of injection. There were no systemic adverse reactions associated with up to 10 weeks of chronic exposure of mice or monkeys to FA-nanoATV/r. /AAC.04108-14.

AB - The drug delivery platform for folic acid (FA)-coated nanoformulated ritonavir (RTV)-boosted atazanavir (FA-nanoATV/r) using poloxamer 407 was developed to enhance cell and tissue targeting for a range of antiretroviral drugs. Such formulations would serve to extend the drug half-life while improving the pharmacokinetic profile and biodistribution to reservoirs of human immunodeficiency virus (HIV) infection. To this end, we now report enhanced pharmacokinetics and drug biodistribution with limited local and systemic toxicities of this novel nanoformulation. The use of FA as a targeting ligand for nanoATV/r resulted in plasma and tissue drug concentrations up to 200-fold higher compared to equimolar doses of native drug. In addition, ATV and RTV concentrations in plasma from mice on a folate-deficient diet were up to 23-fold higher for mice administered FA-nanoATV/r than for mice on a normal diet. Compared to earlier nanoATV/r formulations, FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations. In a drug interaction study, ATV plasma and tissue concentrations were up to 5-fold higher in mice treated with FA-nanoATV/r than in mice treated with FA-nanoATV alone. As observed in mice, enhanced and sustained plasma concentrations of ATV were observed in monkeys. NanoATV/r was associated with transient local inflammation at the site of injection. There were no systemic adverse reactions associated with up to 10 weeks of chronic exposure of mice or monkeys to FA-nanoATV/r. /AAC.04108-14.

UR - http://www.scopus.com/inward/record.url?scp=84912121180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912121180&partnerID=8YFLogxK

U2 - 10.1128/AAC.04108-14

DO - 10.1128/AAC.04108-14

M3 - Article

C2 - 25288084

AN - SCOPUS:84912121180

VL - 58

SP - 7510

EP - 7519

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -